GlassScriptPhysician profile
Kimberly Jordan Tupper
NPI 1437785482
$3,874.81
in general payments reported to CMS, 2019-2025
24 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,931 · 2022: $749 · 2023: $523 · 2024: $325 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.69 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $568.43 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $357.57 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Amarin Pharma, INC. | $339.60 | 2021 | |
| Glaxosmithkline, LLC. | $303.26 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $301.31 | 2021-2025 | |
| Lilly USA, LLC | $288.66 | 2021-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $246.88 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $216.92 | 2021-2024 | Capvaxive |
| Nestle Healthcare Nutrition INC. | $179.83 | 2021-2022 | |
| Pfizer INC. | $153.76 | 2021-2024 | |
| Edwards Lifesciences Corporation | $148.78 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $141.68 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.31 | 2021 | |
| Atricure, INC. | $97.06 | 2023 | |
| Amgen INC. | $86.67 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $81.46 | 2021 | |
| Mylan Specialty L.P. | $58.59 | 2021-2023 | Yupelri |
| Dexcom, INC. | $58.21 | 2023-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $46.83 | 2025 | Cds - Mct/Cem Monitoring |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.20 | 2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $19.83 | 2025 | Voquezna |
| Inogen, INC. | $17.07 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Alexion Pharmaceuticals, INC. | $14.61 | 2021 | |
| Astellas Pharma US INC | $14.29 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Tupper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.